MAZE Earnings & Financial Statements
Maze Therapeutics, Inc.
$26.23
-$0.43(-1.61%)
58
Overall
60
Value
72
Tech
44
Quality
Market Cap
$1.46B
Volume
835.70K
52W Range
$21.95 - $53.65
Target Price
$61.50
MAZE earnings and financial statements: Maze Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
MAZE Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | - | $167.50M | - |
| Cost of revenue | $6.31M | - | - |
| Operating income | -$142.90M | $57.59M | -$98.55M |
| EBITDA | -$128.72M | - | - |
| Net income | -$131.12M | $52.23M | -$100.42M |
| EPS (diluted) | $-3.05 | $1.25 | $-43.89 |
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Total assets | $397.13M | $240.54M | $71.50M |
| Total liabilities | $42.16M | $551.73M | $445.35M |
| Shareholders’ equity | $354.97M | -$311.18M | -$373.85M |
| Cash and equivalents | $189.25M | $196.81M | $29.16M |
| Long-term debt | $18.51M | - | $20.08M |
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Operating cash flow | -$111.94M | $75.95M | -$86.83M |
| Capital expenditure | -$794.0K | - | - |
| Free cash flow | -$112.73M | $74.81M | -$87.27M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MAZE | $26.23 | -1.6% | 835.70K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |